A systematic review of commencing full-dose antihypertensives in newly diagnosed hypertension

Hypertension is the UK’s most common treatable cause of mortality and morbidity, including cardiovascular disease (CVD), renal disease and dementia This systematic review has explored the efficacy and safety of commencing full-dose antihypertensive treatment in individuals with essential hypertension. Method16 randomised controlled trials (RCTs) were eligible for inclusion, with some RCTs assessing more than one treatment. The review assessed commonly used antihypertensive drugs (perindopril 8 mg, ramipril 10 mg, amlodipine 10 mg, losartan 100 mg, irbesartan 300 mg, candesartan 16 mg and candesartan 32 mg) compared to low starting doses or placebo RCTs. Eligible studies included 12 RCTs that compared full vs low doses and 19 RCTs that compared full starting doses vs placebo. The primary outcome was the difference in blood pressure reduction compared to controls (reported or calculated). ResultsUsing full doses compared to low doses led to better BP reduction (overall, 3.9/2.2 mmHg lower achieved BP) without an increase in adverse effects. This notion is supported by the changes achieved with full-dose treatment initiation compared to placebo (average over all studies: 11.4 [4.4]/6.5 [2.9] mmHg). This review indicates that initiating full-dose antihypertensives for essential hypertension may be beneficial and safe. The available data are limited, and further RCTs are required to assess this in specific patient groups to assess safety and efficac. High blood pressure is the leading preventable cause of death and serious illness in the UK. When left untreated, it can lead to heart disease, stroke, kidney problems and dementia. The good news is that high blood pressure is treatable. With proper medication and lifestyle changes, people can significantly reduce their risk of developing serious health problems. We conducted a comprehensive review of the existing research base to determine whether starting high blood pressure patients on full-strength medications from the beginning is more effective and safer than starting with lower doses. We found 16 high-quality studies involving commonly prescribed blood pressure medications, including perindopril, ramipril, amlodipine, losartan and irbesartan. The studies compared full doses versus low starting doses and full doses versus inactive placebo pills. The results showed clear benefits to starting with full-strength medications. When patients began treatment with full doses rather than low doses, their blood pressure dropped. Importantly, starting with full doses did not cause more side effects than beginning with lower doses, suggesting this approach is safe for most patients with essential hypertension (high blood pressure without an underlying cause). These findings suggest that doctors could help patients achieve better blood pressure control more quickly by prescribing full-strength medications from the start, rather than gradually increasing doses over time. However, researchers note that more studies are needed to confirm this approach works safely across different patient populations.